Back to top
more

Nivalis Therapeutics, Inc. (ALPN)

(Delayed Data from NSDQ)

$6.24 USD

6.24
7,474

-0.08 (-1.27%)

Updated May 3, 2019 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alpine Immune Sciences Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Alpine Immune Sciences has been struggling lately, but the selling pressure may be coming to an end soon.

Analysts Estimate Alpine Immune Sciences (ALPN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Alpine Immune Sciences (ALPN) Q1 Earnings Expected to Decline

by Zacks Equity Research

Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: CMS Energy, Alpine Immune Sciences, Kohl's, Franklin Resources and Dominion Energy

by Zacks Equity Research

The Zacks Analyst Blog Highlights: CMS Energy, Alpine Immune Sciences, Kohl's, Franklin Resources and Dominion Energy

Tirthankar Chakraborty headshot

5 Best Stocks to Buy Ahead of Q1 Earnings Season

by Tirthankar Chakraborty

Total earnings for the S&P 500 companies are estimated to drop 4% from the same period last year, which would be the first quarterly decline since 2016. Revenues are expected to rise 4.6%.

Will Nivalis Therapeutics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Nivalis Therapeutics.

The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

Kinjel Shah headshot

Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

by Kinjel Shah

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

Top Ranked Momentum Stocks to Buy for March 15th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 15th:

Analysts Estimate Alpine Immune Sciences (ALPN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in FibroGen (FGEN): Stock Soars 48.2%

by Zacks Equity Research

FibroGen (FGEN) was a big mover last session, as the company saw its shares rise over 48% on the day amid huge volumes.

    Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session

    by Zacks Equity Research

    Corcept Therapeutics Incorporated (CORT) moved big last session, as its shares rose over 8% on the day.

      Tirthankar Chakraborty headshot

      New Strong Buy Stocks for August 2nd

      by Tirthankar Chakraborty

      Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday